
- Pharmaceutical Executive-07-01-2016
- Volume 36
- Issue 7
Pill Counters
Pharm Exec adds up some interesting figures from recent industry news.
Pharm Exec adds up some interesting figures from recent industry news.
13, 55, 47
The number of suspensions or program holds in Alzheimer’s disease in Phase III, Phase II or IIb, and Phase I, respectively, according to a BioMedTracker analysis by
1,234
Pipeline products in active development for hematological cancers, according to GBI Research. Leukemia leads the pack with 798 products in active development.
7 years
The extension to AstraZeneca’s market exclusivity for Crestor that the company argues it should earn under the Orphan Drug Act for gaining approval to treat rare pediatric cases of homozygous familial hypercholesterolemia, or HoFH, according to
61.5%
The percentage of Phase I trials in oncology launched in 2014-2015 that involved more than one primary drug, according to a Trialtrove analysis in May’s
14 million
The number of sprays of FluMist that were projected to be dosed out next fall by MedImmune, the division of AstraZeneca, accounting for about 8% of the nation’s flu vaccine supply. However, an expert CDC panel says the nasal puff should not be used this year because there is no evidence to support that it has protected flu evaders over the last three years, writes
$8,700
The median monthly price of patent-protected branded cancer drugs, David Crow writes for the
10 million deaths, $100 trillion lost
Forecasts for the number of yearly deaths in 2050 and the losses in global economic production by mid-century, according to a May report commissioned by the UK government,
. The report’s chairman Jim O’Neil admits the figures could overestimate the building crisis, but considering the fact that new strains continue to pop up, the report could be overly cautious. He points to innumerable secondary factors, using examples such as the possibility that caesarian sections and hip replacements might become prohibitively risky. The industry’s unwillingness to commit capital tells the story of an unclear path to profitability. Of $38 billion of venture capital funding that was put toward pharmaceutical R&D from 2003 to 2013, only $1.8 billion was allocated for antimicrobial drugs.
A shortage of antibiotics but no shortage of apps …
43%
The portion of iOS apps of about 1,000 patient-facing health apps targeting chronic diseases that were found useful (27% for Android), according to a Commonwealth Fund funded
Casey McDonald is Pharm Exec’s Senior Editor. He can be reached at
Articles in this issue
over 9 years ago
Keeper of the Name: Bayer's Habib Dableover 9 years ago
Worlds Beyond the Clinicover 9 years ago
'PRIME' Time for Medicines in the EUover 9 years ago
Country Report: Italy, Part 2over 9 years ago
Pharmaceutical Executive, July 2016 Issue (PDF)Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.